This Month in Psychopharmacology

Orexin-2 Receptor Agonist Shows Preliminary ADHD Symptom Improvement

Orexin A and orexin B are neuropeptides produced by neurons concent...

Read More

FDA Approves First Once-Monthly Subcutaneous Olanzapine for Schizophrenia

The U.S. Food and Drug Administration (FDA) has approved olanzapine...

Read More

FDA Approves Tavapadon for Adults with Parkinson Disease

The U.S. Food and Drug Administration (FDA) has approved tavapadon ...

Read More

Elevating ADHD Awareness Through Clinical Practice

October is ADHD Awareness Month. The goal of ADHD Awareness Month i...

Read More

Ketamine Transiently Alters Brain Network Dynamics Linked to Rumination and Somatosensory Processing

Ketamine produces rapid antidepressant effects and has been report...

Read More

Eptinezumab Shows Sustained Real-World Benefits in Difficult-to-Treat Migraine

Migraine prevention can be particularly challenging in patients wit...

Read More

DT120 Lysergide ODT Receives FDA Breakthrough Therapy Designation for Major Depressive Disorder

Definium Therapeutics announced on September 8, 2026, that the US F...

Read More

World Suicide Prevention Day

Education matters for suicide prevention. National and regional sui...

Read More

Lithium Treatment May be Associated With Lower Cardiovascular Risk in Bipolar Disorder

Lithium remains a first-line treatment with established benefits fo...

Read More

SGLT2 Inhibitor Use Associated With Lower Dementia Risk in Older Adults With Psychiatric Disorders

A recent study suggest that sodium-glucose cotransporter 2 (SGLT2) ...

Read More

Suicide Prevention: Cross-Diagnostic Strategies in Clinical Care

Join us at the 2026 NEI Fall Congress, for a CME/CE session presen...

Read More

GLP-1 Receptor Agonists Are Associated With Lower Mortality in Serious Mental Illness

People with serious mental illness (SMI) die 10 to 25 years earlier...

Read More